...
首页> 外文期刊>Pharmacoepidemiology and drug safety >Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
【24h】

Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.

机译:在儿科患者的骨髓移植白消安剂量的贝叶斯个体化之后,对静脉闭塞性疾病进行风险调整后的监测。

获取原文
获取原文并翻译 | 示例

摘要

In order to assess the performance of Bayesian individualization of busulfan (BU) dosage regimens, veno-occlusive disease (VOD) rate was monitored for paediatric patients undergoing allogeneic bone marrow transplantation (BMT). Consecutive patients undergoing allogeneic BMT with BU as conditioning regimen during 5-years period (January 2000-February 2006) were reviewed. VOD was a major outcome variable. Preconditioning risk of VOD was estimated for each patient using a scoring system that included type of transplant, recipient CMV-positive status and total parenteral nutrition (TPN) provided pretransplantation. A risk-adjusted cumulative sum method was used to compare observed versus predicted outcome by assigning a risk score, based on log-likelihood ratios, to each patient. These cumulative scores were sequentially plotted with preset control limits for 'signalling' where results were substantially different than expected (doubling or halving of odds ratio). Sixty-six children received BMT after oralbusulfan-based conditioning regimen with median age 3.9 years, 63.6% of male. Median preconditioning risk of VOD was 0.34 ranging from 0.23 to 0.84. Observed VOD rate was 16.7% (n = 11) which was 60.7% (17) fewer than the expected number estimated by the risk score. The resulting risk-adjusted score for each patient was plotted sequentially. This plot adopted early a negative slope, crossing the lower control limit twice, after 27 and 66 patients, indicating improved results compared to those expected. Bayesian individualization of oral busulfan dosage regimens is useful to reduce the VOD rate in children undergoing allogeneic BMT.
机译:为了评估白消安(BU)给药方案的贝叶斯个性化方法的性能,监测了接受异基因骨髓移植(BMT)的小儿患者的静脉闭塞性疾病(VOD)率。回顾了在5年期间(2000年1月至2006年2月)连续接受异基因BMT和BU作为条件治疗方案的患者。 VOD是主要的结果变量。使用评分系统评估每位患者的VOD预处理风险,评分系统包括移植类型,受体CMV阳性状态和移植前提供的总肠胃外营养(TPN)。通过基于对数似然比为每位患者分配风险评分,使用了风险调整的累积总和方法来比较观察到的结果和预测的结果。将这些累积分数与“信号”的预设控制范围相继绘制,结果明显不同于预期(比值比增加一倍或减半)。 66名儿童在口服以白消安为基础的条件治疗后接受了BMT,中位年龄为3.9岁,占男性的63.6%。 VOD的中位预处理风险为0.34,范围为0.23至0.84。观察到的VOD率为16.7%(n = 11),比风险评分估计的预期数字低60.7%(17)。依次绘制每个患者的风险调整后得分。该图在27例和66例患者后早期采用了负斜率,两次越过了控制下限,表明与预期相比结果有所改善。口服白消安剂量方案的贝叶斯个体化可用于降低接受异基因BMT的儿童的VOD率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号